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The less mucoid strain of Brucella canis or M- strain is
used for the serologic diagnosis of canine brucellosis.
While this strain is avirulent in dogs, we report the case of
clinical brucellosis that developed in a laboratory worker a
few days after handling live M- cells for antigen production.
Brucella canis is the causative agent of canine brucel-losis, which causes contagious abortion, orchiepi-
didymitis, and uveitis. Transmission to human requires
close contact with infected animals or bacterial cultures.
Symptomatic human infections are rare, probably because
of the low virulence of B. canis; 31 human cases have been
reported (1). 
In contrast to other Brucella species, which are patho-
genic for humans (B. abortus, B. melitensis, B. suis) and
yield smooth colonies, B. canis colonies are naturally
rough. Therefore, serologic tests that use suspensions of
smooth brucellae are not useful in diagnosing B. canis
infections (2). Since suspensions of wild-type B. canis tend
to aggregate even in the absence of specific antibodies, a
less mucoid variant termed M-, which does not produce
autoagglutination is used for serologic diagnosis (3). The
M- strain has reduced virulence in dogs; even high doses
of this strain do not induce the typical signs of brucellosis
in dogs (4). The pathogenic potential of the M- strain in
humans remains unknown, and to the best of our knowl-
edge, human infection by this strain has not been reported.
We report a clinical and immunologic study of a human
infection by the B. canis M- strain that shows that this
strain can produce human disease similar to that produced
by wild-type B. canis. 
Case Report
A 35-year-old male laboratory worker was referred to a
physician with recurrent fever, headache, arthralgia, weak-
ness, and constipation, which had begun 1 month before.
The patient worked in a laboratory that produced antigens
for diagnostic use. Three weeks before symptoms began,
he had been handling a dense culture of live B. canis M-
and was using no personal protection; the procedures were
not performed in a biological safety cabinet. Moreover, the
patient had attempted resuspension by repeated pipetting
with his mouth. The clinical examination disclosed cervi-
cal adenomegaly, and laboratory tests indicated a mild
increase of hepatic enzymes (Aspartate aminotransferase
46 U/L and alanine aminotransferase 65 U/L) and neu-
tropenia. The patient reported not having close contact
with dogs or other animals. Taking into account the unpro-
tected exposure to B. canis M-, brucellosis was suspected,
and blood samples were drawn for culture and serologic
studies. Two weeks later blood cultures indicated a
Brucella species that was later typed as B. canis.
Conventional tests for antibodies to smooth brucellae
(agglutination, complement fixation) yielded negative
results. In contrast, slide agglutination for B. canis was
strongly positive with undiluted serum and was also posi-
tive at 1:10 dilution. Serologic tests for hepatotropic virus-
es and Toxoplasma gondii were negative. 
After diagnosis, a course with oral doxycycline, 100 mg
twice a day for 42 days, plus parenteral gentamicin, 180
mg once a day for 10 days, was started. The patient clini-
cally recovered, but on the last day gentamicin was admin-
istered, symptoms of VIII cranial nerve involvement
occurred, which resolved with flunarizine and vitamin B12
administration.
Blood cultures performed 2 weeks after antimicrobial
therapy ended were negative for B. canis. During follow-
up, the patient remained asymptomatic, his cervical adeni-
tis resolved, and serum levels of hepatic enzymes returned
to normal. On his last visit, 4 years after infection, the
patient was asymptomatic. While he continues to handle B.
canis M-, cultures are now performed under strict biologi-
cal safety measures (biological safety cabinet, personal
protection including goggles, gloves and mask, and auto-
claving of contaminated material). 
Immunologic Studies
To assess the humoral immune response of the patient
to Brucella antigens, the slide agglutination test with B.
canis M- and 3 enzyme-linked immunosorbent assays
(ELISA) were used. ELISA used a hot-saline extract of B.
canis M- (HS, mainly composed of rough lipopolysaccha-
ride [LPS] and outer membrane proteins), a preparation of
cytoplasmic proteins of B. abortus depleted of LPS (CP
[cytoplasmic proteins]) or recombinant Brucella lumazine
synthase (RBLS), which were obtained as described previ-
ously (5–7). As shown in the Figure, antibodies to the three
antigens were detected at the time of diagnosis, but anti-
bodies to proteinaceous antigens (CP and RBLS) were
negative earlier than those against HS. The slide agglutina-
tion test that used B. canis M- and undiluted serum was
strongly positive at diagnosis and 48 days later (beginning
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and end of therapy, respectively), weakly positive at 103
and 150 days, and negative at 190 days and 4 years after
diagnosis. Positive samples were assayed in serial dilu-
tions starting at 1:10; only the initial sample was positive
at 1:10 dilution (negative at 1:20).
The cellular immune response against proteinaceous
activity from Brucella in peripheral blood mononuclear
cells (PBMCS) was also evaluated. In vitro proliferation
and cytokine gene expression were investigated as previ-
ously described (8). For blastogenesis assays, PBMCS
were cultured with CP (10 µg/mL), RBLS (5 µg/mL), or
phytohemagglutinin (10 µg/mL). Results were expressed
as stimulation index (counts per minute of stimulated cul-
tures divided by counts per minute of unstimulated cul-
tures). Stimulation indices (SI) >2 were considered posi-
tive. For reverse transcription-polymerase chain reaction
(RT-PCR), RNA was extracted from PBMCS cultured in
the presence of CP, RBLS, or phytohemagglutinin for 24
hours. Results were expressed as fold increase over the
messenger ribonucleic acid levels of cells cultured in the
absence of antigen; increases >2 were considered specific.
CP and RBLS induced T-cell proliferation (SI >2) in
PBMCS obtained from the patient before antimicrobial
therapy (Table). PBMCS from a healthy person, which
were run in parallel, showed no response to CP and RBLS
(SI <2) (not shown). In addition, CP and RBLS induced a
significant (p<0.001, nonparametric Mann-Whitney U
test) upregulation of interferon-gamma (IFN-γ), inter-
leukin (IL)-2, and IL-10 transcripts only in PBMCS from
the patient. No IL-4 induction was observed with PBMCS
from the patient or the healthy control (not shown). The
cellular immune response declined with antimicrobial
treatment (Table), but CP-specific IFN-γ remained
increased 55 days after therapy ended. In the last sample
(obtained 250 days after therapy ended), all the parame-
ters of the cellular immune response were normal (not
shown).
Conclusions
The main finding of our study is that the M- strain of B.
canis can produce human disease, which was unexpected
in view of the reported avirulent phenotype of this strain in
dogs. To the best of our knowledge, this case is the first of
human B. canis M- infection ever reported. The M- strain
has been widely used for the diagnosis of canine brucel-
losis because it is less prone to autoagglutination than its
wild-type counterpart (called M+). Based on the low viru-
lence of the M- strain in dogs (4), the production protocol
of the laboratory where this case occurred did not include
bacterial inactivation or personnel protection during initial
handling of cultures, which led to a prolonged exposure to
a high number of viable bacteria. As the patient was the
only person involved in the production of this strain, his
co-workers were not tested for B. canis M-. Similar illness
in the production plant was not reported. Because Brucella
spp. is not usually transmitted from patients to healthy per-
sons, the patient’s family members were not tested for B.
canis M- infection.
The clinical manifestations in our patient were similar
to those reported for human, wild-type B. canis infections
(e.g., fever, headache, anorexia, asthenia, and adenitis).
Previous studies in dogs experimentally infected with the
M- strain showed that this strain does not revert to the M+
phenotype in vivo (4). Our case may be analogous to cases
of human illness by attenuated strains of Brucella species
used for animal vaccination, mainly B. melitensis Rev-1
(9) and B. abortus S19 (10). Altogether, these human
infections indicate that attenuation for animals does not
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Figure. Serological follow-up of a human infection by Brucella
canis M-. CP, cytoplasmic proteins; BLS, Brucella lumazine syn-
thase; HS, B. canis hot-saline extract. The enzyme-linked
immunosorbent assay (ELISA) titer was calculated as the inverse
of the last serum dilution that yielded an optical density higher than
the cut-off of the assay.
Table. Cellular immune response in vitro to Brucella cytoplasmic proteinsa 
 Antigen Lymphocyte proliferation (SI) IL-2b (fold increase) IFN-γb (fold increase) IL-10b (fold increase) 
BLS 4 8 3 3 Before therapy 
CP 3 10 7 4.5 
BLS 1 1 2 1 End of therapy 
CP 2.5 6 4 2 
BLS 1 1 1 1 55 days after end  
of therapy CP 1 1 3 1 
aBLS, Brucella lumazine synthase; CP, cytoplasmic proteins; SI, stimulation indices; IL, interleukin; IFN, interferon. 
bBy reverse transcription-polymerase chain reaction. 
necessarily mean innocuity for humans and that biological
safety measures must be followed in each case. 
To assess the humoral immune response to the infection
with the M- strain, antibodies against outer membrane
antigens (HS) and to internal antigens (CP and Brucella
lumazine synthase) were measured. Overall, low titers of
antibodies were found by all tests, which is similar to those
found for M- infections in dogs (4). Low antibody titers
also could be related to early administration of antimicro-
bial therapy, as has been shown in patients infected with
smooth brucellae (11). Antibodies to both external and
internal antigens declined after antimicrobial therapy was
begun and were undetectable 6 months after diagnosis
(Figure). This decline, with longer persistence of antibod-
ies to external antigens, is in agreement with our previous
findings in human infections by smooth Brucella species
(12). 
An early and strong cellular Th1-type response to
Brucella internal antigens developed in this patient, in
agreement with our previous observations in acute human
brucellosis (8). The reasons for the decline of this response
during follow-up are unknown, but conceivably, bacteria
levels were substantially diminished by the early antimi-
crobial therapy, thus eliminating the internal antigens
needed to develop a long-lasting cellular immune
response.
In summary, this case shows that, in spite of its reduced
virulence in dogs, B. canis M- can produce human disease
with a clinical picture similar to that produced by the infec-
tion with wild-type strains of B. canis. Therapeutic and
immunologic parameters seem to be very similar to those
observed in infections by smooth brucellae. 
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